50 filings analyzed. Top movers: Host Digital Inc., Huckleberry.ai, Inc., QVC Group, Inc., Beam Global, Jersey Mike's Subs Inc..
8-K/A
Host Digital Inc.
Host Digital Inc. executed an underwriting agreement dated September 17, 2026, with Cantor Fitzgerald as lead underwriter to sell 2,187,500 firm shares at $8.00 per share (gross proceeds ~$17.5M), plus a 30-day option for underwriters to purchase up to 328,125 additional shares at the same price. Net proceeds to the company are approximately $16.3M after the $0.56/share underwriter discount. First closing scheduled for September 21–30, 2026. The company granted a 45-day lock-up on its own share issuances.
▲ Likely positive
· significance 99 · 8-K Agent
8-K
Huckleberry.ai, Inc.
Domo, Inc. completed its sale of substantially all assets and employees to Progress Software Corporation on September 22, 2026. The company has rebranded to Huckleberry.ai, Inc., retaining $221M in cash (~$4.46/share post-adjustments), >$900M in NOL carryforwards, and a debt-free balance sheet. Founder Josh James remains CEO; the company will trade on Nasdaq under ticker HUCK beginning September 24, 2026.
▼ Likely negative
· significance 92 · 8-K Agent
8-K
QVC Group, Inc.
QVC Group, Inc. filed for Chapter 11 bankruptcy on April 16, 2026, in the Southern District of Texas. A prepackaged plan of reorganization was confirmed by the Bankruptcy Court on July 20, 2026, and became effective on August 6, 2026. The company is now operating as a reorganized debtor with 12,500 full-time employees. The August 2026 monthly operating report shows cash balance of $205.4M, cumulative losses of $104.0M through August 5, 2026, and total liabilities of $7.89B against assets of $2.05B, resulting in a deficit of $5.84B.
▼ Likely negative
· significance 92 · 8-K Agent
8-K
Beam Global
Beam Global (market cap ~$23.3M) announced a non-binding Letter of Intent to acquire an unnamed vertically integrated European drone technology company. The target produces drones with U.S. Department of War Conditional Approval and AI-enhanced software. Beam plans to manufacture the drones domestically post-acquisition and sell across its customer base (U.S. Army, Marine Corps, Navy, British MOD, Fortune Global 500 companies). The transaction remains subject to due diligence, financing, and definitive agreement execution with no assurance of completion.
▲ Likely positive
· significance 78 · 8-K Agent
8-K
Jersey Mike's Subs Inc.
Jersey Mike's Subs Inc. filed Form 8-K on September 22, 2026, reporting a change in control of the registrant (Item 5.01). The filing also included other events disclosure (Item 8.01). No specific details regarding the counterparty, transaction value, share counts, or dates of the control change are provided in the available filing header metadata.
— Neutral
· significance 78 · 8-K Agent
8-K
Reborn Coffee, Inc.
On September 16, 2026, Reborn Coffee, Inc. received notice of delisting or failure to satisfy continued listing standards (Item 3.01). No specific exchange, timeline, remediation plan, or financial details are disclosed in the filing header. The company, valued at approximately $10.9M, faces potential loss of public market listing.
▼ Likely negative
· significance 78 · 8-K Agent
8-K
Stardust Power Inc.
Stardust Power Inc. issued $6,076,872 of common stock (par value $0.0001/share) through an at-market offering under a May 8, 2026 Sales Agreement with B. Riley Securities, Inc. The offering was registered on Form S-3 (effective April 16, 2026) with prospectus supplements dated May 8, September 17, and September 22, 2026. This represents a capital raise equivalent to ~62% of the company's current market capitalization (~$9.8M).
▲ Likely positive
· significance 78 · 8-K Agent
S-1
Boxlight Corp
On August 5, 2026, Boxlight issued 937,500 shares of Series D Convertible Preferred Stock ($8.00/share, $7.5M gross proceeds, stated value $10.00) to accredited investors in two tranches ($5.5M funded August 6, 2026; $2M conditional on registration effectiveness). Concurrently, it entered an Equity Purchase Agreement with Secure Net Capital LLC for up to $15M in common stock over 36 months at 95% of VWAP. J.J. Astor Co. (related party controlled by CEO Michael Pope) holds $2.7M outstanding inventory financing convertible into common stock. This Form S-1 registers 47.1M shares for resale (30.4M from preferred conversion at floor price $0.616, 15M from ELOC, 1.43M from J.J. Astor debt conversion).
▼ Likely negative
· significance 78 · Registration Agent
8-K
Tonix Pharmaceuticals Holding Corp.
Tonix announced a second major managed Medicare payer agreement effective immediately, adding approximately 21 million Medicare lives (38% of ~55M total U.S. Medicare lives). This expands total Medicare coverage to 32 million lives (58%) and brings combined commercial and government payer coverage to approximately 166 million lives (53% of ~314M U.S. population). The company also activated approximately 50 new sales representatives, bringing total sales force to 150.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Viking Therapeutics, Inc.
Viking announced positive topline results from its VK2735 maintenance study (VK2735-102) in ~180 obese adults. After 21 weeks of weekly dosing achieving 16-19% weight loss, patients transitioned to maintenance regimens: every-other-week dosing maintained up to 97% of weight loss (vs. 61% placebo, p<0.0001), and monthly dosing maintained up to 90% (vs. 61% placebo, p=0.0002). GI adverse event rates matched placebo during maintenance phase. An exploratory weekly-dosing control arm achieved 21.7% weight loss at week 33 with continued progression and no plateau.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Celldex Therapeutics, Inc.
Celldex announced positive topline results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of barzolvolimab in chronic spontaneous urticaria. Both studies (1,939 patients randomized: 963 in CSU1, 976 in CSU2) met the primary endpoint of mean UAS7 change at Week 12 with both 150 mg Q4W and 300 mg Q8W doses showing highly significant improvements versus placebo (p<0.00001). Complete response rates (UAS7=0) reached 42-46% at Week 12 and 45-54% at Week 24 versus 9-18% placebo. In omalizumab-refractory patients, complete response rates were 41-55% at Week 12. The company plans BLA submission in 2027.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Knightscope, Inc.
Knightscope reported approximately $27 million in estimated renewals, bookings, and client awards from May 20 through September 18, 2026, comprising 109 contracts across seven vertical markets: $19.6M (72%) from renewals with existing clients and $7.4M (28%) from new business. The largest renewal was a $17M three-year master services agreement with a multinational industrial client (no minimum purchase obligation); the largest new engagement was a $5.8M written award from a national retailer. Industrial/Energy/Security Services accounted for $18.7M (69%), Retail/Consumer $6.5M (24%), and other verticals the remainder.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
FILANA THERAPEUTICS, INC.
Filana Therapeutics announced on September 22, 2026, that the FDA lifted its clinical hold on simufilam's IND application, permitting initiation of a Phase 2a proof-of-concept study in 40 patients aged 12–55 with TSC-related epilepsy. The 16-week randomized, double-blind trial will be conducted at 13 U.S. sites with a 48-week optional extension; patient screening begins Q1 2027. Filana holds an exclusive worldwide license from Yale University for simufilam in TSC-related epilepsy, supported by preclinical mouse models showing seizure reduction.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
i-80 Gold Corp.
i-80 Gold released a feasibility study for Granite Creek Underground showing after-tax NPV (5%) of $118 million at $2,750/oz gold, increasing to $598 million at $4,500/oz. The project has 2.20 Mt proven & probable reserves grading 7.87 g/t Au (556,500 oz), with 8.5-year mine life, estimated cash costs of $1,827/oz during steady-state (2028–2032), and total capital of $144.9M. The company also announced positive drill results from Mineral Point open pit, with step-out holes showing up to 1.33 g/t Au and 39.2 g/t Ag over 225.6 m.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
LandBridge Co LLC
LandBridge (market cap ~$1.7B) announced a $100M offering of 6.250% senior notes due 2030 as additional notes under existing indenture (total $500M existing notes), with proceeds to repay revolving credit facility borrowings. Separately, the company acquired 24,000+ surface acres and related assets for ~$261.2M in September 2026, funded with cash and borrowing. Pro forma net leverage increases from 2.5x to 3.3x on Covenant EBITDA basis.
▼ Likely negative
· significance 72 · 8-K Agent
8-K
Compass Therapeutics, Inc.
The FDA recommended Compass conduct a new trial demonstrating survival benefit before submitting a Biologics License Application for tovecimig in previously treated advanced biliary tract cancer, despite positive Phase 2/3 COMPANION-002 results showing statistically significant improvements in ORR (18.0% vs. 5.3%, p=0.0228) and PFS (median 4.7 vs. 2.6 months, HR 0.44, p<0.0001). Compass disagrees with the FDA requirement and intends to further engage with the agency, remaining confident in the data based on the 56% reduction in disease progression risk.
▼ Likely negative
· significance 72 · 8-K Agent
8-K
XFLH Capital Corp
XFLH Capital Corporation, a blank-check SPAC with ~$101.4M in total assets, signed a non-binding letter of intent with Renogen Biolab Inc., a Canadian health services provider offering DNA services, vector engineering, and protein expression capabilities. The parties agreed to negotiate definitive agreements in good faith and conduct mutual due diligence. No financial terms, valuation, share counts, or closing timeline were disclosed in this announcement.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Idaho Copper Corp
On September 9, 2026, the U.S. Forest Service approved Idaho Copper's Exploration Plan of Operations and 2026 annual operating plan for the CuMo copper-molybdenum project in Boise County, Idaho. The approval clears regulatory hurdles for drilling and roadbuilding; the company plans up to 15,000 feet of diamond core drilling in 2026 and a larger 2027 campaign targeting a Prefeasibility Study. The PoO is valid for six years from first operations and follows the March 2025 Environmental Assessment decision.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
SILVER BOW MINING CORP.
Silver Bow Mining signed a non-binding term sheet with Ocean Partners UK Limited on September 22, 2026, for an integrated package worth approximately $88 million comprising: (1) a $40 million concentrate prepayment facility in three tranches (Tranche A: $10M, Tranche B: $20M, Tranche C: $10M at company option) linked to 10-year zinc and lead concentrate offtake agreements for the Rainbow Block and Montana Tunnels Mine; (2) guarantees of approximately $43.1 million in reclamation surety bonds expected to release ~$42 million of cash collateral; (3) a $5 million pre-bridge financing to be funded within five business days; and (4) Ocean Partners' commitment to lead a future $5 million equity investment. The facility bears interest at 12-month SOFR plus 6.75% per annum with a 1% arrangement fee. Final definitive agreements are targeted for Q4 2026 concurrent with Silver Bow Mining's previously announced acquisition of the Jefferson County Metallurgical Complex, subject to customary closing conditions including board and shareholder approvals, DEQ acceptance of replacement surety bonds, and satisfactory due diligence.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Endovia Health Sciences, Inc.
Endovia Health Sciences closed $500,000 in secured convertible debt from C/M Capital Master Fund, LP on September 22, 2026, the first tranche of a previously announced $1 million commitment. Proceeds support development of CannEpil, a cannabinoid veterinary therapeutic in FDA INAD program for canine cancer pain, and international commercialization. Filing emphasizes favorable regulatory backdrop: FDA launched botanical drug development initiative and Congress introduced H.R. 10150 (Advancing Botanical Drug Development Act) proposing 12-year market exclusivity for approved botanical drugs.
▲ Likely positive
· significance 72 · 8-K Agent
10-K
AYTU BIOPHARMA, INC
Effective June 23, 2026, Aytu BioPharma and Lannett Company terminated their License and Distribution Agreement for Metadate CD (methylphenidate ER). Lannett transfers the NDA (New Drug Application 021259) back to Lannett; Aytu retains rights to sell existing inventory with royalty payments to Lannett continuing until inventory is depleted. No dollar amounts, royalty percentages, or inventory quantities are disclosed in the termination agreement.
▼ Likely negative
· significance 72 · Periodic Agent
8-K
Rocket One Inc.
Rocket One Inc. signed a definitive agreement on September 18, 2026, to acquire 100% of Tracer Drone Technologies LLC, a New Jersey-based drone hardware, software, training, and services provider. The agreement specifies acquisition of all issued and outstanding membership interests; no purchase price, stock consideration, or earn-out terms are disclosed in this filing. Tracer will operate as a wholly owned subsidiary post-closing, expected to provide revenue-generating operations and a commercial channel for Rocket One's AI and counter-UAS technologies.
▲ Likely positive
· significance 72 · 8-K Agent
SCHEDULE 13D
TriplePoint Venture Growth BDC Corp.
Four TriplePoint-affiliated entities (TriplePoint Capital LLC, TPC Intermediate LLC, TriplePoint Capital Holdings LLC, and Madera Ventures LLC) filed a joint Schedule 13D on September 22, 2026, disclosing beneficial ownership of approximately 11.6 million shares of TriplePoint Venture Growth BDC Corp. common stock. Key beneficial owners include James P. Labe (2.56M shares), Michael Gontar (3.02M shares), and Robert W. Toan (2.99M shares). The filing establishes a joint reporting arrangement among these related entities and their managers.
— Neutral
· significance 72 · Ownership Agent
8-K
Elmet Group Co.
Elmet Group signed a long-term offtake agreement with Tungsten West plc to purchase >1,000 metric tonnes per year of tungsten concentrate from the Hemerdon Mine in Devon, England, valued at >$230 million annually at current prices. The agreement supports a U.S.-UK critical materials partnership, complementing the U.S. Department of War's $450 million investment in Elmet announced September 14, 2026, and the UK government's £71 million investment in Tungsten West. Production ramp-up at Hemerdon targets end of Q1 2027.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Tessera Defense & Homeland Security Inc.
Tessera amended its August 5, 2026 Share Purchase Agreement with Mayers Ventures LLC to increase its equity stake in M.E.A. Testing Systems Ltd. from 10% to 15% (486,860 shares: 257,973 ordinary + 228,887 preferred). Consideration increased to 195,000 Tessera restricted shares (~4.5% of Tessera's outstanding stock post-reverse-split) plus a $475,000 convertible loan facility at 12% annual interest, maturing in 2 years, convertible at 4× EBITDA (capped at $10M, floored at $2M). Tessera also granted M.E.A. an exclusive perpetual, royalty-free license to Tessera's drone-testing technology. Deal remains subject to NYSE American approval; closing has not yet occurred.
— Neutral
· significance 72 · 8-K Agent
8-K
Plutonian Acquisition Corp. II
Plutonian Acquisition Corp. II (Cayman Islands SPAC, ~$109M assets) agreed to merge with NT1 Pty Ltd (Australian mineral exploration company focused on rare earths/critical minerals in Western Australia/Northern Territory). The Company Shareholders receive $500M in Purchaser Shares valued at $10/share (50M shares). Closing Exchange Consideration may adjust post-valuation; Outside Date June 30, 2027. Transaction includes SPAC merger into subsidiary, liquidation of Predecessor, and equity incentive pool up to 10% fully-diluted.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
FortuneX Acquisition Corp
WT Realty Group Inc. (real estate tech/brokerage platform) will merge with FortuneX Acquisition Corp (SPAC) in an all-stock transaction. Company shareholders will receive 60 million shares of PubCo Class A/B Common Stock (60M shares at $10 reference price = $600M equity value). SPAC has ~$88.1M in trust; post-closing, Company shareholders will hold ≥51% voting power. Transaction subject to SPAC shareholder vote, regulatory approvals, and closing conditions through May 26, 2027 outside date.
▲ Likely positive
· significance 72 · 8-K Agent
SCHEDULE 13D/A
Funko, Inc.
Fund 1 Investments, LLC executed extensive trading in Funko common stock over 60 days (07/27/2026–09/21/2026). Net activity: purchased approximately 2,150,000 shares and sold approximately 1,380,000 shares, resulting in a net long position increase of ~770,000 shares. Purchase prices ranged from $5.32–$7.27; sale prices ranged from $5.26–$7.27. This Schedule 13D/A amendment reflects significant accumulation by the filer.
▲ Likely positive
· significance 72 · Ownership Agent
8-K
Lucid Diagnostics Inc.
Lucid Diagnostics announced three regulatory wins: (1) CMS Medicare Advisory Panel recommended maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule (PLA code 0114U, effective CY2021); (2) AMA CPT Editorial Panel approved a new Category III CPT code for non-endoscopic cell collection with EsoCheck; (3) CDC/NCHS ICD-10 Committee favorably received proposed diagnosis code R85.83 for positive EsoGuard results. Lucid began Medicare claims submission in Texas immediately and will do so in California once LCD is finalized. No dollar amounts or share counts disclosed.
▲ Likely positive
· significance 68 · 8-K Agent
8-K
PROGRESS SOFTWARE CORP /MA
Progress Software completed acquisition of substantially all assets of Domo's AI and data platform business for $400M, funded via cash and revolving credit facility. Acquisition adds 2,400+ customer base and strategic cloud data warehouse partnerships. Transaction strengthens Progress's data governance and AI platform capabilities.
▲ Likely positive
· significance 68 · 8-K Agent
8-K
Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals announced FDA Fast Track Designation for QRX003 (topical serine protease inhibitor) for Peeling Skin Syndrome (PSS) on September 22, 2026—the first-ever Fast Track for any PSS therapy. This is QRX003's second Fast Track designation (Netherton Syndrome received the first on March 11, 2026). The company plans to initiate a Phase 2/3 study in H2 2026 enrolling up to 12 pediatric and adult patients in the U.S. and Europe, targeting 2028 approval; no dollar amounts or equity transactions are disclosed.
▲ Likely positive
· significance 68 · 8-K Agent
8-K
NN INC
NN Inc raised full-year 2026 guidance on Sept 22, 2026: net sales increased from $460–480M to $470–490M (midpoint $480M, +14% YoY); adjusted EBITDA increased from $55–65M to $58–68M (midpoint $63M, +29% YoY). Growth driven by $94M new business wins YTD in Data Center, Defense Electronics, and Medical; company expects $100M total 2026 wins. TTM Q2 2026 net sales $455.8M; adjusted EBITDA margin 12.6%, targeting 14% by 2029. No share counts or specific dollar counterparties named.
▲ Likely positive
· significance 68 · 8-K Agent
8-K
GREENBRIER COMPANIES INC
Greenbrier received 3,400 railcar orders valued at approximately $600 million in fiscal Q4 2026 (ended August 31). The order includes 780 units for Saudi Arabian government-owned SAR comprising tank cars (phosphoric acid, molten sulfur) and intermodal units—the first intermodal sale to SAR, expanding a relationship that began in 2015. The order represents roughly 35% of company market capitalization and signals strong international demand.
▲ Likely positive
· significance 62 · 8-K Agent
8-K
Solaris Energy Infrastructure, Inc.
Solaris Energy Infrastructure announced a $1.0 billion offering of Senior Notes due 2032 on September 22, 2026, to fund general corporate purposes and growth capital expenditures. The company plans to increase revolving credit facility commitments by $200M (from $650M to $850M) and increase letter of credit sublimit from $150M to $325M. Proceeds support capacity expansion from ~950 MW (Q2 2026) to 3,300+ MW by end of 2029, with three major customer contracts totaling ~2,200 MW: Stateline (~900 MW, 7-year tenor), Hatchbo (~660 MW, 10+8-year option), and Customer C (~640 MW, 10+5-year option).
▲ Likely positive
· significance 62 · 8-K Agent
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.